JP2013537901A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537901A5
JP2013537901A5 JP2013529758A JP2013529758A JP2013537901A5 JP 2013537901 A5 JP2013537901 A5 JP 2013537901A5 JP 2013529758 A JP2013529758 A JP 2013529758A JP 2013529758 A JP2013529758 A JP 2013529758A JP 2013537901 A5 JP2013537901 A5 JP 2013537901A5
Authority
JP
Japan
Prior art keywords
aprepitant
proline
neuropsychiatric
pruritus
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013529758A
Other languages
English (en)
Japanese (ja)
Other versions
JP5997162B2 (ja
JP2013537901A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/054210 external-priority patent/WO2012038937A1/en
Publication of JP2013537901A publication Critical patent/JP2013537901A/ja
Publication of JP2013537901A5 publication Critical patent/JP2013537901A5/ja
Application granted granted Critical
Publication of JP5997162B2 publication Critical patent/JP5997162B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013529758A 2010-09-23 2011-09-23 アプレピタントl−プロリン組成物および共結晶 Active JP5997162B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US38574410P 2010-09-23 2010-09-23
US61/385,744 2010-09-23
US201161439654P 2011-02-04 2011-02-04
US61/439,654 2011-02-04
US201161498214P 2011-06-17 2011-06-17
US61/498,214 2011-06-17
PCT/IB2011/054210 WO2012038937A1 (en) 2010-09-23 2011-09-23 Aprepitant l-proline composition and cocrystal

Publications (3)

Publication Number Publication Date
JP2013537901A JP2013537901A (ja) 2013-10-07
JP2013537901A5 true JP2013537901A5 (enExample) 2016-02-12
JP5997162B2 JP5997162B2 (ja) 2016-09-28

Family

ID=44907915

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013529758A Active JP5997162B2 (ja) 2010-09-23 2011-09-23 アプレピタントl−プロリン組成物および共結晶

Country Status (13)

Country Link
US (1) US9029369B2 (enExample)
EP (1) EP2618828B1 (enExample)
JP (1) JP5997162B2 (enExample)
KR (1) KR101833578B1 (enExample)
CN (1) CN103221049B (enExample)
AR (1) AR083095A1 (enExample)
AU (1) AU2011306391B2 (enExample)
BR (1) BR112013006651A2 (enExample)
CA (1) CA2846460C (enExample)
ES (1) ES2616752T3 (enExample)
IL (1) IL225443A0 (enExample)
TW (1) TWI540131B (enExample)
WO (1) WO2012038937A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101833578B1 (ko) 2010-09-23 2018-02-28 누포믹스 리미티드 아프레피탄트 l-프롤린 조성물 및 공결정
US9532993B2 (en) 2011-11-25 2017-01-03 Nuformix Limited Aprepitant L-proline solvates—compositions and cocrystals
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
JP2017502973A (ja) * 2013-12-30 2017-01-26 オンコプレフェント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を予防する方法において使用するためのニューロキニン−1受容体アンタゴニスト
US10717755B2 (en) 2018-02-07 2020-07-21 Reata Pharmaceuticals, Inc. Co-crystal forms of a novobiocin analog and proline
CN116283947A (zh) * 2023-02-07 2023-06-23 成都医学院 一种阿瑞匹坦共晶及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5719147A (en) 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
ZA985765B (en) 1997-07-02 1999-08-04 Merck & Co Inc Polymorphic form of a tachykinin receptor antagonist.
AU2003243699B2 (en) 2002-06-21 2009-01-15 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
AU2003272270A1 (en) * 2003-02-28 2004-09-28 The Regents Of The University Of Michigan Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2007147160A2 (en) * 2006-06-16 2007-12-21 Dr. Reddy's Laboratories Ltd. Aprepitant compositions
EP2254555A4 (en) * 2008-02-27 2013-10-09 Reddys Lab Ltd Dr APREPITANT FORMS WITH INCREASED SOLUBILITY AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
KR101833578B1 (ko) 2010-09-23 2018-02-28 누포믹스 리미티드 아프레피탄트 l-프롤린 조성물 및 공결정

Similar Documents

Publication Publication Date Title
JP2013537901A5 (enExample)
JP2014502641A5 (enExample)
JP2013525444A5 (enExample)
JP2011522816A5 (enExample)
JP2009541216A5 (enExample)
JP2013522326A5 (enExample)
JP2013237682A5 (enExample)
JP2010504973A5 (enExample)
JP2010248252A5 (enExample)
JP2019503365A5 (enExample)
JP2010535252A5 (enExample)
JP2007504174A5 (enExample)
JP2014530220A5 (enExample)
JP2012508215A5 (enExample)
JP2010514806A5 (enExample)
JP2020534270A5 (enExample)
JP2011516417A5 (enExample)
JP2014516942A5 (enExample)
JP2008539267A5 (enExample)
JP2013522230A5 (enExample)
JP2008539268A5 (enExample)
JP2013541583A5 (enExample)
JP2012523395A5 (enExample)
JP2009511568A5 (enExample)
JP2012509279A5 (enExample)